These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 16176283

  • 1. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin.
    Meingassner JG, Aschauer H, Stuetz A, Billich A.
    Exp Dermatol; 2005 Oct; 14(10):752-7. PubMed ID: 16176283
    [Abstract] [Full Text] [Related]

  • 2. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
    Stuetz A, Grassberger M, Meingassner JG.
    Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
    [Abstract] [Full Text] [Related]

  • 3. Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function.
    Krummen MB, Varga G, Steinert M, Stuetz A, Luger TA, Grabbe S.
    Exp Dermatol; 2006 Jan; 15(1):43-50. PubMed ID: 16364030
    [Abstract] [Full Text] [Related]

  • 4. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
    Grassberger M, Steinhoff M, Schneider D, Luger TA.
    Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
    [Abstract] [Full Text] [Related]

  • 5. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
    Weiss HM, Fresneau M, Moenius T, Stuetz A, Billich A.
    Drug Metab Dispos; 2008 Sep; 36(9):1812-8. PubMed ID: 18524871
    [Abstract] [Full Text] [Related]

  • 6. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
    Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG.
    Int Arch Allergy Immunol; 2006 Sep; 141(3):199-212. PubMed ID: 16926539
    [Abstract] [Full Text] [Related]

  • 7. StabiEL: stabilization of skin condition with Elidel--a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.
    Gollnick H, Luger T, Freytag S, Bräutigam M, STABIEL study group.
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1319-25. PubMed ID: 18540990
    [Abstract] [Full Text] [Related]

  • 8. Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test.
    Engel K, Reuter J, Seiler C, Schulte Mönting J, Jakob T, Schempp CM.
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):447-50. PubMed ID: 18031501
    [Abstract] [Full Text] [Related]

  • 9. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
    Ständer S, Ständer H, Seeliger S, Luger TA, Steinhoff M.
    Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
    [Abstract] [Full Text] [Related]

  • 10. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
    Lerche CM, Philipsen PA, Poulsen T, Wulf HC.
    Exp Dermatol; 2009 Mar; 18(3):246-51. PubMed ID: 19183401
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
    Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y.
    Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
    [Abstract] [Full Text] [Related]

  • 12. Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.
    Gschwind HP, Waldmeier F, Zollinger M, Schweitzer A, Grassberger M.
    Eur J Pharm Sci; 2008 Jan; 33(1):9-19. PubMed ID: 17996430
    [Abstract] [Full Text] [Related]

  • 13. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.
    Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, Henz BM.
    J Allergy Clin Immunol; 2001 Aug; 108(2):275-80. PubMed ID: 11496246
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.